Henrik Paavilainen
Overview
Explore the profile of Henrik Paavilainen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luostarinen A, Vuorela A, Kerkela E, Patrikoski M, Kotovuori A, Koski J, et al.
Sci Rep
. 2025 Mar;
15(1):8093.
PMID: 40057567
There is a growing demand for chimeric antigen receptor (CAR) -T cells for clinical trials. Consequently, new centers capable of manufacturing advanced therapy medicinal products (ATMPs) are needed. In this...
2.
Palomaki J, Kalke K, Orpana J, Lund L, Frejborg F, Paavilainen H, et al.
Microorganisms
. 2023 Nov;
11(11).
PMID: 38004669
Herpes simplex virus (HSV) has proven successful in treating human cancer. Since the approval of talimogene laherparepvec (T-VEC) in 2015, HSV has been thoroughly researched to discover novel mechanisms to...
3.
Kalke K, Lund L, Nyman M, Levanova A, Urtti A, Poranen M, et al.
PLoS Pathog
. 2022 Jul;
18(7):e1010688.
PMID: 35793357
Herpes simplex virus type 1 (HSV-1) is a common virus of mankind and HSV-1 infections are a significant cause of blindness. The current antiviral treatment of herpes infection relies on...
4.
Kalke K, Orpana J, Lasanen T, Esparta O, Lund L, Frejborg F, et al.
Viruses
. 2022 Jun;
14(6).
PMID: 35746761
Herpes simplex virus type 1 (HSV-1) is the only FDA- and EMA- approved oncolytic virus, and accordingly, many potential oncolytic HSVs (oHSV) are in clinical development. The utilized oHSV parental...
5.
Kalke K, Lehtinen J, Gnjatovic J, Lund L, Nyman M, Paavilainen H, et al.
Viruses
. 2020 Dec;
12(12).
PMID: 33322225
Acyclovir is the drug of choice for the treatment of herpes simplex virus (HSV) infections. Acyclovir-resistant HSV strains may emerge, especially during long-term drug use, and subsequently cause difficult-to-treat exacerbations....
6.
Levanova A, Kalke K, Lund L, Sipari N, Sadeghi M, Nyman M, et al.
Antiviral Res
. 2020 Aug;
182:104916.
PMID: 32798603
Chemical modifications of small interfering (si)RNAs are used to enhance their stability and potency, and to reduce possible off-target effects, including immunogenicity. We have earlier introduced highly effective antiviral siRNA...
7.
Bowen C, Paavilainen H, Renner D, Palomaki J, Lehtinen J, Vuorinen T, et al.
J Virol
. 2019 Feb;
93(8).
PMID: 30760568
A majority of adults in Finland are seropositive carriers of herpes simplex viruses (HSV). Infection occurs at epithelial or mucosal surfaces, after which virions enter innervating nerve endings, eventually establishing...
8.
Ylosmaki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, et al.
Mol Ther
. 2018 Jul;
26(9):2315-2325.
PMID: 30005865
The approval of the first oncolytic virus for the treatment of metastatic melanoma and the compiling evidence that the use of oncolytic viruses can enhance cancer immunotherapies targeted against various...
9.
Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, et al.
Antiviral Res
. 2018 Apr;
154:174-182.
PMID: 29698664
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal...
10.
Herpes simplex and human papilloma virus coinfections in oral mucosa of men-A 6-year follow-up study
Maki J, Paavilainen H, Kero K, Hukkanen V, Syrjanen S
J Med Virol
. 2017 Oct;
90(3):564-570.
PMID: 28975630
Herpes simplex virus (HSV) establishes latency in neurons and recurrent infections in oral mucosa. This prospective study analyzes HSV prevalence in oral mucosal brush samples from men with known human...